ATRC
AtriCure, Inc.
Latest Form 4:Sale$458KbyDahlquist Karl S. (Chief Legal Officer) · filed Aug 26, 2026
AtriCure, Inc. (ATRC) has 39 SEC Form 4 filings (59 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 26, 2026.
The most active filer is Chief Scientific Officer Doraiswamy Vinayak with 3 filings. Insiders have net sold $2.5M over the trailing 6 months.
- Industry:Medical - Instruments & Supplies
- CEO:Michael H. Carrel
- Employees:1,300
- HQ:Mason, OH, US
- IPO:2005-08-05
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.3M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$2.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Dahlquist Karl S.First filing | Chief Legal Officer | Sale | 9,370 | $458K | Aug 26 | SEC ↗ |
| Director | Sale | 3,564 | $138K | Aug 7 | SEC ↗ | |
Yuen MaggieFirst in 5 months | Director | Sale | 3,500 | $134K | Aug 7 | SEC ↗ |
| Chief Scientific Officer | Sale | 6,000 | $233K | Jul 30 | SEC ↗ | |
| Director | Sale | 25,000 | $946K | Jul 30 | SEC ↗ | |
Noznesky Justin JFirst in 8 months | Chief Mktg & Strategy Officer | Sale | 6,182 | $240K | Jul 30 | SEC ↗ |
Prange KarenFirst filing | Director | Sale | 3,000 | $86K | May 22 | SEC ↗ |
| Chief Scientific Officer | Sale | 5,000 | $141K | May 18 | SEC ↗ | |
Doraiswamy VinayakFirst filing | Chief Scientific Officer | Sale | 5,000 | $149K | Mar 16 | SEC ↗ |
WEHRWEIN SVENFirst filing | Director | Sale | 5,033 | $188K | Nov 26 | SEC ↗ |
WEHRWEIN SVENFirst filing | Director | Sale | 4,967 | $189K | Nov 26 | SEC ↗ |
| Chief Mktg & Strategy Officer | Sale | 5,166 | $193K | Nov 26 | SEC ↗ | |
Yuen MaggieFirst filing | Director | Sale | 3,000 | $107K | Nov 25 | SEC ↗ |
Noznesky Justin JFirst filing | Chief Mktg & Strategy Officer | Sale | 3,000 | $109K | Sep 16 | SEC ↗ |
Related companies
AtriCure, Inc. is in the Healthcare sector.